Yestar Healthcare Holdings
Market Cap
HK$3.0b
Last Updated
2020/11/23 12:52 UTC
Data Sources
Company Financials +
Executive Summary
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Mediocre balance sheet with moderate growth potential.
Share Price & News
How has Yestar Healthcare Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 2393 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 2393's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
0%
2393
5.0%
HK Medical Equipment
1.1%
HK Market
1 Year Return
-5.9%
2393
97.7%
HK Medical Equipment
8.3%
HK Market
Return vs Industry: 2393 underperformed the Hong Kong Medical Equipment industry which returned 97.7% over the past year.
Return vs Market: 2393 underperformed the Hong Kong Market which returned 8.3% over the past year.
Shareholder returns
| 2393 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0% | 5.0% | 1.1% |
| 30 Day | -2.3% | 3.3% | 5.6% |
| 90 Day | 5.0% | -10.0% | 3.7% |
| 1 Year | -5.9%-5.9% | 98.9%97.7% | 12.8%8.3% |
| 3 Year | -61.8%-62.5% | 158.1%151.5% | -2.8%-12.9% |
| 5 Year | -60.2%-61.9% | 234.3%218.1% | 30.6%8.5% |
Long-Term Price Volatility Vs. Market
How volatile is Yestar Healthcare Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Returns On Capital At Yestar Healthcare Holdings (HKG:2393) Paint An Interesting Picture1 month ago | Simply Wall St
How Much Did Yestar Healthcare Holdings' (HKG:2393) CEO Pocket Last Year?1 month ago | Simply Wall St
We Think Yestar Healthcare Holdings (HKG:2393) Is Taking Some Risk With Its DebtValuation
Is Yestar Healthcare Holdings undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2393 (HK$1.27) is trading below our estimate of fair value (HK$10.07)
Significantly Below Fair Value: 2393 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2393 is unprofitable, so we can't compare its PE Ratio to the HK Medical Equipment industry average.
PE vs Market: 2393 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2393's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 2393 is overvalued based on its PB Ratio (4.3x) compared to the HK Medical Equipment industry average (3.8x).
Next Steps
Future Growth
How is Yestar Healthcare Holdings forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
56.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2393 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).
Earnings vs Market: 2393 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2393's is expected to become profitable in the next 3 years.
Revenue vs Market: 2393's revenue (11.5% per year) is forecast to grow slower than the Hong Kong market (13.8% per year).
High Growth Revenue: 2393's revenue (11.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2393's Return on Equity is forecast to be low in 3 years time (10.5%).
Next Steps
Past Performance
How has Yestar Healthcare Holdings performed over the past 5 years?
-18.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2393 is currently unprofitable.
Growing Profit Margin: 2393 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2393 is unprofitable, and losses have increased over the past 5 years at a rate of 18.1% per year.
Accelerating Growth: Unable to compare 2393's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2393 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.7%).
Return on Equity
High ROE: 2393 has a negative Return on Equity (-84.53%), as it is currently unprofitable.
Next Steps
Financial Health
How is Yestar Healthcare Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 2393's short term assets (CN¥3.1B) exceed its short term liabilities (CN¥2.5B).
Long Term Liabilities: 2393's short term assets (CN¥3.1B) exceed its long term liabilities (CN¥1.8B).
Debt to Equity History and Analysis
Debt Level: 2393's debt to equity ratio (239.6%) is considered high.
Reducing Debt: 2393's debt to equity ratio has increased from 81.1% to 239.6% over the past 5 years.
Debt Coverage: 2393's debt is well covered by operating cash flow (37.5%).
Interest Coverage: 2393 is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is Yestar Healthcare Holdings's current dividend yield, its reliability and sustainability?
6.78%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2393's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2393's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2393's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2393's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 2393 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 2393's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
James Hartono (44 yo)
no data
Tenure
CN¥3,722,000
Compensation
Mr. James Hartono serves as the Chairman of The Board and Chief Executive Officer of Yestar Healthcare Holdings Company Limited (formerly known as Yestar International Holdings Company Limited). Mr. Harton...
CEO Compensation Analysis
Compensation vs Market: James's total compensation ($USD567.05K) is above average for companies of similar size in the Hong Kong market ($USD342.47K).
Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | no data | CN¥3.72m | 26.26% CN¥ 791.9m | |
| CFO & Executive Director | 8.75yrs | CN¥879.00k | no data | |
| Chief Operating Officer | 2.67yrs | CN¥2.69m | no data | |
| Executive Director | 7.75yrs | CN¥1.78m | no data | |
| Executive Director | no data | no data | no data | |
| Company Secretary | 5.5yrs | no data | no data | |
| Chief Executive Officer of Shanghai Emphasis Investment Management Consulting Co Ltd | 5.25yrs | no data | 6.99% CN¥ 210.7m |
5.3yrs
Average Tenure
45yo
Average Age
Experienced Management: 2393's management team is seasoned and experienced (5.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | no data | CN¥3.72m | 26.26% CN¥ 791.9m | |
| CFO & Executive Director | 8.75yrs | CN¥879.00k | no data | |
| Executive Director | 7.75yrs | CN¥1.78m | no data | |
| Executive Director | no data | no data | no data | |
| Independent Non-Executive Director | 7.17yrs | CN¥204.00k | no data | |
| Independent Non-Executive Director | 7.17yrs | CN¥204.00k | no data | |
| Independent Non-Executive Director | 7.17yrs | CN¥204.00k | no data |
7.2yrs
Average Tenure
45yo
Average Age
Experienced Board: 2393's board of directors are considered experienced (7.2 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Yestar Healthcare Holdings Company Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Yestar Healthcare Holdings Company Limited
- Ticker: 2393
- Exchange: SEHK
- Founded: 1971
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: HK$3.016b
- Shares outstanding: 2.36b
- Website: https://www.yestarcorp.com
Number of Employees
Location
- Yestar Healthcare Holdings Company Limited
- Green Land Building
- Floor 8, Block A
- Shanghai
- Shanghai Province
- 201199
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2393 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Yes | Ordinary Shares | HK | HKD | Oct 2013 |
Biography
Yestar Healthcare Holdings Company Limited, an investment holding company, engages in the manufacture, distribution, and sale of medical imaging products in Mainland China. It operates through two segments...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/11/23 12:52 |
| End of Day Share Price | 2020/11/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.